23 November 2023

Adams plc

("Adams" or the "Company")

Interim Results for the Six Months ended 30 September 2023

Chairman's Statement

Adams generated a net profit of £0.29 million for the six months ended 30 September 2023 compared to a loss of £1.03 million in the six months ended 30 September 2022.

The half year profit of £0.29 million comprises a net investment profit return of £0.39 million, less overhead costs of £0.10 million. The comparative 2022 half year loss of £1.03 million included a net investment loss return of £0.95 million, together with administrative costs of £0.08 million.

During the half year, the Company spent £0.21 million on a new quoted equity investment in NCC Group Plc and realised disposal proceeds of £0.34 million on the sale of its Afrenta Plc and Tremor International Ltd investments in full, together with a partial sale of its Seeing Machines Ltd investment holding.

The carrying value of the Company's equity investments at 30 September 2023 was £5.31 million represented by eight quoted investment holdings and three private investments (31 March 2023: £5.10 million represented by nine quoted investment holdings and three private investments). In addition, Adams holds a derivative investment asset in the form of warrants in C4X Holdings Plc which have an exercise price that is significantly above the market price of the underlying shares and the warrants are therefore considered to have a nil fair value.

The Company held cash balances of £0.12 million as at 30 September 2023, compared to cash balances of £0.05 million at the previous 31 March 2023 year end.

Net assets increased to £5.40 million (equivalent to 3.70p per share) at the 30 September 2023 balance sheet date, compared with £5.11 million (equivalent to 3.50p per share) at 31 March 2023. The £0.29 million increase in net assets reflects the profit reported for the half year.

Business model and investing policy

Adams is an investing company with an investing policy under which the Board is seeking to acquire interests in special situation investment opportunities that have an element of distress, dislocation, dysfunction or other special situation attributes and that the Board perceives to be undervalued. The principal focus is in the small to middle-market capitalisation sectors in the UK or Europe, but the Directors will also consider possible special situation opportunities anywhere in the world if they believe there is an opportunity to generate added value for shareholders.

Investment Portfolio

The principal listed investments held by the Company at 30 September 2023 (each representing at least 5% of the net asset value of the Company at that date) comprised Niox Group Plc ("Niox"), C4X Discovery Holdings Plc ("C4XD"), Seeing Machines Limited ("Seeing Machines"), Griffin Mining Limited ("Griffin") and Access Intelligence Plc ("Access Intelligence"). Adams also holds Oxehealth Limited ("Oxehealth") and Telit Cinteron Ltd ("Telit") as principal unquoted investments.

Niox is an AIM listed global medical device company focused on point of care FeNO testing for the diagnosis and management of asthma. The NIOX VERO® device is the market leader in point of care testing and is approved and reimbursed in most major markets. The group is progressing its transition to a distributor led model with new arrangements in the USA and China expected to drive scalable growth as it continues to implement access to a large and underserved population of patients suffering from asthma. For the half year ended 30 June 2023, sales increased 21% to £18.8 million and generated an EBITDA profit of £6.2 million. The profit after tax for the period amounted to £3.4 million. The company had net cash balances of £27.3 million at 31 August 2023 but subsequently paid out £10.5 million by way of a special 2.5 pence per share dividend in September 2023. The shareholding of Adams at 30 September 2023 was, and continues to be, 0.37 per cent of the Niox shares in issue.

C4XD is a pioneering drug discovery company combining its enhanced DNA-based target identification and candidate molecule design capabilities to efficiently deliver world‑leading medicines which are developed by licensing partners. C4XD has a number of existing partnership deals including a milestone and royalties out-licensing agreement with Sanofi for its IL-17A inhibitor programme worth up to €414 million plus potential for single‐digit royalties and also an exclusive licensing agreement with AstraZeneca for its NRF2 activator programme addressing the treatment of inflammatory and respiratory diseases. The AstraZeneca agreement is worth up to $402 million including pre-clinical milestone payments of up to $16 million ahead of the first clinical trial, with $2 million upfront. In addition, the company has continued to drive other key programmes towards partnering with a near term focus on inflammatory and oncology diseases. C4XD reported a loss after tax of £3.9 million in the six months ending 31 January 2023 inclusive of R&D investment of £5.2 million and with revenues of £1.7 million. Cash balances at 31 January 2023 amounted to £9.6 million. Subsequently, in August 2023, C4XD announced that its cash position would be strengthened by a £15.95 million consideration settlement from Indivior UK Limited to acquire the proprietary rights to the oral Orexin-1 receptor antagonist partnership programme for the treatment of opioid addiction disorders which Indivior would now take fully in-house. The shareholding of Adams in C4XD at 30 September 2023 was, and continues to be, 1.98 per cent of the C4XD shares in issue.

Seeing Machines is an AIM listed industry leader in advanced computer vision technologies. The company designs Artificial Intelligence / AI powered operator monitoring systems using camera-based optics and embedded processing to improve transport safety in automotive, commercial fleet, aviation, rail and off-road markets. The technology incorporates warnings when human state attention impairment is identified, in order to re-engage the operator or driver. Seeing Machines continues to invest in R&D and grow as an automotive leader in such technology having now won contracts with a total of 10 automotive Tier 1 global customers covering 15 automotive driver monitoring safety ("DMS") programmes. A total of 6 OEM programs have now started production, and at 30 June 2023, Seeing Machines' technology was installed in over 1 million vehicles globally. In the year to 30 June 2023, Seeing Machines also signed an exclusive licence Agreement with Collins Aerospace generating licence revenue over three years of US$10m, to jointly develop pioneering eye-tracking solutions for the Aviation industry. Seeing Machines reported underlying revenue growth of 48% per cent during that year to 30 June 2023, to give revenues of $57.8 million and a loss for the period of $15.5 million. Seeing Machines' cash balances at 30 June 2023 amounted to $36.1 million. The shareholding of Adams in Seeing Machines as at 30 September 2023 was, and continues to be, 0.31 per cent of the Seeing Machines shares in issue.

Griffin Mining Limited, which is an AIM listed mining and investment company that has been the leader in foreign investment in mining in China having been engaged in developing the Caijiaying zinc and gold project since 1997. In January 2021, Griffin announced a major achievement in finally securing a significant new mining license from the Chinese Ministry of Land and Natural Resources which elevates Griffin to being one of the largest zinc producers in China. Revenues more than doubled to US$69.5 million for the 6 months 30 June 2023 and generated a profit after tax of US$5.2 million. The results benefited from record amounts of ore mined and processed and a significant improvement in the market price for zinc and lower smelter treatment charges. Cash balances at 30 June 2023 amounted to US$46.9 million and given the severely undervalued nature of the company's share price, the Griffin Directors also announced a share buy-back programme which was commenced in September 2023. The shareholding of Adams in Griffin as at 30 September 2023 was, and continues to be, 0.25 per cent of the Griffin shares in issue.

Access Intelligence is an AIM listed London based technology innovator delivering Artificial Intelligence / AI Software-as-a-Service solutions for the global marketing and communications industries. The company combines AI technologies with human expertise to analyse data and provide strategic insights as a single, real-time view of what is important. It is supported by partnerships with the world's largest data providers and social media platforms including X (formerly Twitter), Reddit and Twitch. For the 6 months ended 31 May 2023, Access Intelligence reported revenues of £31.3 million and delivered a positive EBITDA of £2.0 million before exceptional costs associated with the integration of Isentia Group which had been acquired in September 2021. This reflected its first six-month period of Annual Recurring Revenue ("ARR") growth in the APAC region since the acquisition of Isentia, alongside continued ARR growth in the EMEA & NA market. The loss for the period amounted to £5.1 million after exceptional costs and inclusive of additional investment in sales and marketing to drive global expansion. Cash balances at 31 May 2023 amounted to £2.7 million. As a result of the restructuring actions taken over the last two years to optimise profitable growth and free cash flow generation, the Access Intelligence Board anticipates the delivery of higher EBITDA and cash generation in the second half. The shareholding of Adams in Access Intelligence as at 30 September 2023 was, and continues to be, 0.52 per cent of the Access Intelligence voting shares in issue.

Oxehealth is a private company and an industry leader in vision-based patient monitoring and management systems. The company uses proprietary signal processing and computer vision to process normal digital video camera data to measure the vital signs and activity of patients in a number of different markets, primarily in Mental Health, Acute Hospital settings, Primary Care settings, Care Home, and Custodial facilities in both the UK and also in Sweden and more recently the USA. This is achieved through the deployment of its Oxevision platform which enables clinicians to take non-contact cardiorespiratory measurements of a patient's pulse and breathing rate, and which generate alerts to potentially risky activity and reports on a patient's vital signs and behaviour. This can all be done without the clinician entering the patient's room, including by use of mobile handsets on the ward. The Oxehealth Service is used by 50% of English NHS mental health trusts as well as acute hospitals, care homes, skilled nursing facilities, prisons and police forces in the UK and Europe. At 30 September 2023, the investment holding by Adams in Oxehealth represents 2.22 per cent of Oxehealth's issued share capital at that date.

Telit is a private company and a global leader in Internet of Things (IoT) enablement. Telit has over twenty years of experience designing, building, and executing complex digital business. The company has an extensive portfolio of wireless connectivity modules, software platforms and global IoT connectivity services, including cellular plans and cloud and data orchestration software. These have empowered hundreds of millions of connected 'things' to date, and are trusted by thousands of direct and indirect customers, globally. On 1 January 2023, the company completed a transaction with the global defence, aerospace and security group, Thales, under which it acquired the cellular IoT products business of Thales and thereby expanded Telit's presence in the growing industrial IoT segments and end markets, including payment systems, energy, e-health, and in the rapidly growing cybersecure IoT solutions market. At 30 September 2023, the investment holding by Adams in Telit represents 0.35 per cent of Telit's issued share capital at that date.

In addition to the above investments, at 30 September 2023 Adams held three other quoted holdings, together with one other private company holding. The three quoted holdings comprise NCC Group Plc, which is FTSE All-Share listed and a leading independent provider of global cyber security and resilience services, focusing on the fastest growing sectors, specifically those which are highly-regulated and most exposed to cyber risk; WANdisco Plc, which  is a data activation company that enables organisations to move large datasets to the cloud at massive scale in order to activate all their data for AI, machine learning and analytics on modern cloud data platforms; and Euromax Resources Ltd, which is a Canadian development company listed on the Toronto Stock Exchange and focused on building and operating the Ilovica-Shtuka copper and gold project in Macedonia;. The private company holding comprises Source Bioscience International Ltd, which is an international provider of state-of-the art laboratory services, clinical diagnostics and analytical testing services.

Outlook

World economies are currently facing many risks and geopolitical uncertainties including the terrible current conflicts in Gaza and Ukraine, together with ongoing trade tensions between the US and China. As a result, continued volatility is expected in financial markets. In addition, whilst the global economy proved more resilient than expected in the first half of 2023, the overall growth outlook in the coming year remains weak and is weighed down by still high inflation and interest rates which may remain higher for longer. Growth forecasts for 2024 are generally strongest in emerging Asian economies, and weakest in Europe and the US.

Difficult and volatile financial market conditions subsequent to our 30 September 2023 half year end have adversely impacted Adams's investment portfolio and have generated unrealised investment losses which are estimated to have now resulted in an overall loss of £0.15 million for the just under 8 months year to date.

In view of the above risks and uncertainties, your Board will continue to maintain a rigorous and highly selective investment approach, coupled with strict cost control with a view to delivering additional value for shareholders going forward. We remain confident in the underlying fundamentals, technologies and long-term potential for growth at the companies within our investment portfolio.

Michael Bretherton

Chairman

23 November 2023

Certain information contained in this announcement would have been deemed inside information for the purposes of UK Market Abuse Regulation until the release of this announcement.

The Directors of the Company take responsibility for this announcement.

Enquiries:

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.